Garcia-Manero and Zeidan Highlight Key Implications of the COMMANDS Trial in Lower-Risk MDS

Author(s):

Drs Garcia-Manero and Zeidan discuss the significance of efficacy and safety data from the COMMANDS trial in myelodysplastic syndrome, takeaways from the subgroup analyses, and expectations around treatment sequencing in the lower-risk population.

Welcome to OncLive On Air^®! I’m your host today, Ashling Wahner.

OncLive On Air^® is a podcast from OncLive^®, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive^® covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions.

In today’s episode, sponsored by Bristol Myers Squibb, Guillermo Garcia-Manero, MD, and Amer Zeidan, MBBS, MHS, discussed important elements of the phase 3 COMMANDS trial (NCT03682536) in lower-risk myelodysplastic syndromes (MDS).

Garcia-Manero is a professor in the Department of Leukemia, chief of the Section of Myelodysplastic Syndromes, deputy chair of Translational Research, and fellowship program director in the Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center in Houston.

Zeidan is an associate professor of internal medicine (hematology) at Yale School of Medicine; director of Early Therapeutics Research in Hematology, leader of the Clinical Research Team for Leukemias and Myeloid Malignancies, and interim chief of Hematologic Malignancies at Yale Cancer Center in New Haven, Connecticut.

In our exclusive interview, Drs Garcia-Manero and Zeidan discussed the significance of efficacy and safety data from the COMMANDS trial in MDS, takeaways from the subgroup analyses, and expectations around treatment sequencing in the lower-risk population.

___

That’s all we have for today! Thank you for listening to this episode of OncLive On Air^®, sponsored by Bristol Myers Squibb. Check back on Mondays and Thursdays for exclusive interviews with leading experts in the oncology field.

For more updates in oncology, be sure to visit www.OncLive.com and sign up for our e-newsletters.

OncLive^® is also on social media. On Twitter, follow us at @OncLive. On Facebook, like us at OncLive, and follow our OncLive page on LinkedIn.

If you liked today’s episode of OncLive On Air^®, please consider subscribing to our podcast on Apple Podcasts, Spotify, Google Podcasts, Amazon Music, and many of your other favorite podcast platforms,* so you get a notification every time a new episode is posted. While you are there, please take a moment to rate us!

Thanks again for listening to OncLive On Air^®.

*OncLive On Air^® is available on: Apple Podcasts, Google Podcasts, Spotify, Amazon Music, Audacy, CastBox, Deezer, iHeart, JioSaavn, Listen Notes, Player FM, Podcast Addict, Podchaser, RadioPublic, and TuneIn.